As a result, endocrinopathies are frequently part of the clinical spectrum of PMM2-CDG, particularly hypergonadotrophic hypogonadism and pubertal abnormalities in female patients. This evidence concerns the gene PMM2 and Hypergonadotropic hypogonadism.